Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Xeris Biopharma Expects To Generate 2024 Revenue Of $203M, Exceeding Previous Guidance Of $198M-$202M Versus Consensus Of $199.70M, With Over $71M In Cash, Cash Equivalents, And Short-term Investments, Generating Positive Cash Flow In The Fourth Quarter

Author: Benzinga Newsdesk | January 10, 2025 08:17am

Other Fourth Quarter 2024 Updates

Recorlev achieved record number of new starts and referrals.
Gvoke ended the year with approximately 35% market share.
Keveyis maintained a similar number of patients on therapy as Q3 2024.
Beta Bionics, Inc.: Xeris successfully formulated a unique XeriSol formulation of glucagon for bi-hormonal pumps and pump systems. This triggered a milestone payment of $3 million in the fourth quarter.
Amgen: Amgen chose to terminate its exclusive worldwide license agreement with Xeris following a broader company portfolio assessment. Their decision was not related to the performance of the XeriJect formulation technology. The termination will not have a material impact on Xeris' outlook.

Posted In: XERS